about
Laboratory measures of methylphenidate effects in cocaine-dependent patients receiving treatmentBaseline neurocognitive profiles differentiate abstainers and non-abstainers in a cocaine clinical trialWorking memory fMRI activation in cocaine-dependent subjects: association with treatment responseUsing addiction severity profiles to differentiate cocaine-dependent patients with and without comorbid major depression.Effects of escitalopram on attentional bias to cocaine-related stimuli and inhibitory control in cocaine-dependent subjects.Relationship between impulsivity and decision making in cocaine dependence.Bradycardia as a Marker of Chronic Cocaine Use: A Novel Cardiovascular Finding.Psychiatric aspects of impulsivity.Replacement medication for cocaine dependence: methylphenidate.A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence.Smoking cessation in women with cardiac risk.Increased intra-individual reaction time variability in cocaine-dependent subjects: role of cocaine-related cuesDemographic and psychological factors associated with lifetime cocaine use: An exploratory factor analysis of baseline questionnaires.Increased Orbitofrontal Brain Activation after Administration of a Selective Adenosine A(2A) Antagonist in Cocaine Dependent SubjectsSerotonin transporter gene promoter polymorphism predicts relationship between years of cocaine use and impulsivityAnti-saccade error rates as a measure of attentional bias in cocaine dependent subjects.A stage I pilot study of acceptance and commitment therapy for methadone detoxificationCombination of Modafinil and d-amphetamine for the Treatment of Cocaine Dependence: A Preliminary Investigation.Effects of oxytocin on aggressive responding in healthy adult men.Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platformPrevalence of traumatic brain injury in cocaine-dependent research volunteers.Substance abuser impulsivity decreases with a nine-month stay in a therapeutic community.Neural correlates of impulsive aggressive behavior in subjects with a history of alcohol dependence.Behavioral therapies trials: a case example.Baby's Breath II protocol development and design: a secondhand smoke exposure prevention program targeting infants discharged from a neonatal intensive care unit.Cocaine dependence and concurrent marijuana use: a comparison of clinical characteristics.Use of stimulants to treat cocaine and methamphetamine abuse.Using prize-based incentives to enhance daily interactive voice response (IVR) compliance: a feasibility studyBiomarkers for the development of new medications for cocaine dependence.A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone.Cognitive-behavioral therapies for depression and substance use disorders: An overview of traditional, third-wave, and transdiagnostic approaches.A preliminary longitudinal study of white matter alteration in cocaine use disorder subjects.Bupropion and naltrexone for smoking cessation: A double-blind randomized placebo-controlled clinical trial.Hospital length of stay in individuals with schizophrenia with and without cocaine-positive urine drug screens at hospital admission.Cue reactivity in cocaine-dependent subjects: effects of cue type and cue modality.Fluoxetine treatment of cocaine-dependent patients with major depressive disorder.The role of avoidance and inflexibility in characterizing response to contingency management for cocaine use disorders: A secondary profile analysis.Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy.Concurrent treatment for alcohol and tobacco dependence: are patients ready to quit both?Moderate- vs high-dose methadone for opioid dependence.
P50
Q28369446-9B6436BC-EE5C-492B-8452-564828BB87E9Q33658928-AAF1EFE2-4964-4D20-BEA4-1AA00B88147FQ33705453-ACD4C360-7B63-4DB8-B452-8167A68E944DQ33725099-CA4C7C24-41BC-4B5F-9B15-B25B49B23C0DQ33753053-CF169ABD-87AF-403D-802D-13158577F08CQ33994455-C5E05FFA-82A6-4F88-81D8-7B0DE376735EQ34173796-4610EA83-C3DD-4D92-B8AA-1A7F14C4BC1FQ34426838-49BC2E5C-AA7E-41A2-B8CA-4F2DD4060925Q34450408-3F7EDDAA-3301-4604-B687-B00220D1C916Q34578600-FC990593-182A-4054-A26A-D12CF74F27FCQ35558994-7F435AF0-198C-4AA2-B87E-10114CF664AEQ35659398-E3C978BF-8B57-44E9-849E-E2BAE3FEAE35Q35838639-EAD6D882-B4F5-45FC-942E-AF48723FBD2AQ35990520-6DDD1449-923C-4A7B-9E21-4F2FA61F29BBQ35995397-40777FD6-3A0D-4260-B143-A80A4B78F2EFQ36021787-A041C17A-8B87-46DD-968F-E22151835A64Q36066920-19D473D9-8147-463E-9C8E-F99D4A7AF20AQ36199252-4D0D87BA-3C9C-4E03-A464-3E517E84593AQ36244735-CA8CD210-1135-4341-8C2A-F0CE90AA5D9AQ36540636-45756270-61FD-492D-A84A-CED3D0DA5487Q36650493-5B8AE944-7AF5-454F-970E-AC853328C19BQ36650498-252A64FE-9BB8-4796-8CA9-6DE0451E1D37Q36650521-F9569B61-C9DB-4FDC-A555-73B276E4017DQ36681225-1186BF1A-8317-415B-9A7F-B13B94D0EE61Q37063676-D09F9842-F94C-4277-B82E-A5001D23C778Q37210803-11B84805-E500-483A-8EFA-D7EAA90A01FCQ37273932-09F0CD34-793D-4B9D-A4D1-E9452408F691Q37282232-01C5241B-A4CA-489F-B3D5-446C7BEDE0FDQ37379480-001A183E-EB69-44F7-8576-ACDD093375A0Q37621846-D8B77F02-663E-494C-9625-1D12D831D598Q38919605-B738A554-223E-45E6-99A1-829A58ADF62AQ38963927-B50C8B06-205A-4025-810A-F2E895149A3EQ41638053-9F0078E9-2A63-42CE-B7AD-5526D56D87E1Q41712162-7FC76CE5-7A73-4E2D-AA65-96BA79DBFB2CQ42544999-FFEB97D8-9940-4620-9669-731BC09A1794Q43647878-2A049340-2ABD-4620-8D69-D18D150AD85AQ43760409-34BCB27E-7609-40C0-996C-9F6FA4F83B7AQ44118248-F0E49C00-13A8-4244-B7AA-58B6A2C3AFD2Q44283687-6EE97B30-3D06-4B87-A4A5-B72C37677B11Q44353240-7EDE5E82-4D1C-4D8F-AC36-71FD65924925
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Joy M Schmitz
@ast
Joy M Schmitz
@en
Joy M Schmitz
@es
Joy M Schmitz
@nl
type
label
Joy M Schmitz
@ast
Joy M Schmitz
@en
Joy M Schmitz
@es
Joy M Schmitz
@nl
prefLabel
Joy M Schmitz
@ast
Joy M Schmitz
@en
Joy M Schmitz
@es
Joy M Schmitz
@nl
P106
P1153
7202546233
P31
P496
0000-0002-3561-4614